文献速递介入腹部CTDSA

无水顺铂混悬液与顺铂乳剂在碘化油经动脉化疗栓塞治疗肝细胞癌中的随机临床试验

Ethiodized Oil-based Transarterial Chemoembolization for Hepatocellular Carcinoma: Randomized Clinical Trial of Anhydrous Cisplatin Suspension versus Cisplatin Emulsion.
PubMed 文献 · Radiology · 2025-01-01

这项前瞻性多中心随机对照试验纳入77例肝细胞癌患者,比较无水顺铂混悬液与常规水相顺铂乳剂在碘化油经动脉化疗栓塞中的疗效与安全性。结果显示混悬液组6个月完全肿瘤缓解率90%高于乳剂组47%,中位无进展生存期21.1个月高于10.4个月(HR 0.35),中位总生存期53.3个月高于36.0个月(HR 0.32),严重不良事件两组相似。

要点

  • 无水顺铂混悬液组6个月完全肿瘤缓解率90%(35/39),显著高于乳剂组47%(18/38),P < .001。
  • 混悬液组中位无进展生存期21.1个月(95%CI 14.3, 38.9),乳剂组10.4个月(95%CI 7.3, 13.4),HR 0.35,P < .001。
  • 混悬液组中位总生存期53.3个月(95%CI 40.5, 未达到),乳剂组36.0个月(95%CI 25.7, 46.6),HR 0.32,P = .004。

核心结论

  • 使用无水顺铂混悬液的碘化油经动脉化疗栓塞在完全肿瘤缓解率、无进展生存期和总生存期方面均优于常规水相顺铂乳剂。

研究设计与样本

  • 前瞻性、多中心、随机对照试验,2016年9月至2023年2月在香港三家医院进行,共纳入77例参与者(中位年龄68岁,IQR 64-75岁,59例男性),按1:1随机分为实验组和对照组。

诊断标准与关键数值

  • 实验组接受无水顺铂混悬液(4 mL碘化油加20 mg顺铂粉末),对照组接受常规水相顺铂乳剂;随机分组后4周内进行经动脉化疗栓塞,共2至3次治疗,间隔2个月;在后续经动脉化疗栓塞期间用CT和数字减影血管造影评估缓解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Despite transarterial chemoembolization (TACE) serving as the first-line treatment for patients with intermediate stage B hepatocellular carcinoma (HCC), complete response rates are generally below 27%. Purpose To compare the efficacy and safety of an anhydrous cisplatin suspension in ethiodized oil-based TACE versus a conventional aqueous cisplatin emulsion in the treatment of participants with HCC. Materials and Methods In this prospective, multicenter, randomized controlled trial conducted from September 2016 to February 2023, participants from three hospitals in Hong Kong were randomized to an experimental or control group in a 1:1 ratio. The experimental group received an anhydrous cisplatin suspension (4 mL of ethiodized oil with 20 mg of cisplatin powder). The control group received a conventional aqueous cisplatin emulsion. TACE was performed within 4 weeks after randomization in two to three treatments, 2 months apart. Response was assessed with CT and digital subtraction angiography during subsequent TACE. Primary end points were complete tumor response and severe adverse events. Secondary end points included progression-free survival and overall survival (OS). Survival outcomes were compared using the log-rank test and hazard ratios with 95% CIs. Results A total of 77 participants were included (median age, 68 years; IQR, 64-75 years; 59 men). At 6 months, the complete tumor response rate was higher in the suspension group (90% [35 of 39 participants]) compared with the emulsion group (47% [18 of 38 participants]; P < .001). Serious adverse events were similar in the suspension group (2.3% [three of 128 procedures]) and emulsion group (5.2% [eight of 153 procedures]; P = .21). Median progression-free survival was higher in the suspension group (21.1 months; 95% CI:14.3, 38.9) compared with the emulsion group (10.4 months; 95% CI: 7.3, 13.4) (hazard ratio, 0.35; P < .001). Median OS was higher in the suspension group (53.3 months; 95% CI: 40.5, not reached) than in the emulsion group (36.0 months; 95% CI: 25.7, 46.6) (hazard ratio, 0.32; P = .004). Conclusion Ethiodized oil-based TACE using an anhydrous cisplatin suspension resulted in better complete tumor response, progression-free survival, and OS rates compared with the conventional aqueous cisplatin emulsion. ClinicalTrials.gov identifier NCT03268499 © RSNA, 2025 Supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Yu SCH, Chan L, Lee KF, et al. Ethiodized Oil-based Transarterial Chemoembolization for Hepatocellular Carcinoma: Randomized Clinical Trial of Anhydrous Cisplatin Suspension versus Cisplatin Emulsion. Radiology. 2025. PMID: 41288481. doi:10.1148/radiol.242982

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。